Literature DB >> 28726025

Synthesis of new tricyclic imidazotriazepine derivatives condensed with various heterocycles.

Tamás Földesi1, András Dancsó2, Péter Slégel2, Balázs Volk2, Mátyás Milen2.   

Abstract

Previously synthesized 9-aryl-5H-imidazo[2,1-d][1,2,5]triazepin-6(7H)-ones have been used as starting materials for the synthesis of three new tricyclic ring systems, where an imidazotriazepine is condensed with an imidazole, triazole or tetrazole ring. These novel compounds could be potential drug candidates for central nervous system diseases because of their closely related structure to known tricyclic derivatives with anticonvulsant activity.

Entities:  

Keywords:  Bioisosteric replacement; Condensation; Cyclization; Heterocycles; Nitrogen heterocycles; Ring closure

Mesh：

Substances：

Year:  2017        PMID： 28726025     DOI： 10.1007/s11030-017-9765-4

Source DB:  PubMed          Journal:  Mol Divers        ISSN： 1381-1991            Impact factor:   2.943


  15 in total

1.  Anxiolytic homophthalazines increase Fos-like immunoreactivity in selected brain areas of the rat.

Authors:  M Palkovits; J S Baffi; P Berzsenyi; E J Horváth
Journal:  Eur J Pharmacol       Date:  1997-07-16       Impact factor: 4.432

2.  Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist.

Authors:  Maria Zappalà; Giovanna Postorino; Nicola Micale; Salvatore Caccamese; Nunziatina Parrinello; Giovanni Grazioso; Gabriella Roda; Frank S Menniti; Giovambattista De Sarro; Silvana Grasso
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

Review 3.  Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.

Authors:  Jarogniew J Luszczki
Journal:  Pharmacol Rep       Date:  2009 Mar-Apr       Impact factor: 3.024

4.  Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists.

Authors:  Rosaria Gitto; Maria Zappal; Sarro Giovambattista De; Alba Chimirri
Journal:  Farmaco       Date:  2002-02

5.  A new psychoactive 5H-2,3-benzodiazepine with a unique spectrum of activity.

Authors:  K Horváth; F Andrási; P Berzsenyi; M Pátfalusi; M Patthy; G Szabó; L Sebestyén; E Bagdy; J Körösi; P Botka
Journal:  Arzneimittelforschung       Date:  1989-08

6.  Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.

Authors:  Fabio M Iwamoto; Teri N Kreisl; Lyndon Kim; J Paul Duic; John A Butman; Paul S Albert; Howard A Fine
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

7.  Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones.

Authors:  S Grasso; G De Sarro; A De Sarro; N Micale; S Polimeni; M Zappalà; G Puia; M Baraldi; C De Micheli
Journal:  Bioorg Med Chem Lett       Date:  2001-02-26       Impact factor: 2.823

8.  New non competitive AMPA antagonists.

Authors:  G Abrahám; S Sólyom; E Csuzdi; P Berzsenyi; I Ling; I Tarnawa; T Hámori; I Pallagi; K Horváth; F Andrási; G Kapus; L G Hársing; I Király; M Patthy; G Horváth
Journal:  Bioorg Med Chem       Date:  2000-08       Impact factor: 3.641

9.  Synthesis of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2, 3-benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists.

Authors:  Y Wang; C S Konkoy; V I Ilyin; K E Vanover; R B Carter; E Weber; J F Keana; R M Woodward; S X Cai
Journal:  J Med Chem       Date:  1998-07-02       Impact factor: 7.446

10.  Structure-activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent.

Authors:  Nicola Micale; Simona Colleoni; Giovanna Postorino; Alessia Pellicanò; Maria Zappalà; John Lazzaro; Valentina Diana; Alfredo Cagnotto; Tiziana Mennini; Silvana Grasso
Journal:  Bioorg Med Chem       Date:  2007-12-05       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.